Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.65 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876482 | 0.85 | PGR (0.64) | PGRNR3C1 | |
| SCHEMBL3870568 | 0.80 | PGR (0.69) | PGRARNR3C1NR3C2 | |
| SCHEMBL3870550 | 0.80 | PGR (0.66) | PGRARNR3C1NR3C2 | |
| SCHEMBL4179192 | 0.79 | PGR (0.82) | PGRARNR3C1NR3C2 | |
| SCHEMBL3876137 | 0.79 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL3872257 | 0.78 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL3883683 | 0.77 | PGR (0.86) | PGRARNR3C1NR3C2 | |
| SCHEMBL4167996 | 0.77 | PGR (0.65) | PGRARNR3C1NR3C2 | |
| SCHEMBL7157408 | 0.76 | PGR (0.64) | PGRARNR3C1NR3C2 | |
| SCHEMBL7590404 | 0.76 | PGR (0.64) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | claimed |
| CN-1179753-C | Contraceptive compositions contaiing antiprogesting and progestinic | — | 2004-12-15 | — | — | CN | claimed |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2004-09-23 | — | — | US | claimed |
| EP-1173210-B1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | WYETH CORP (US) | 2004-09-15 | — | — | EP | claimed |
| US-6759408-B2 | CYCLIC COMBINATION THERAPIES AND REGIMENS UTILIZING SUBSTITUTED INDOLINE DERIVATIVE COMPOUNDS WHICH ARE ANTAGONISTS OF THE PROGESTERONE RECEPTOR | WYETH | 2004-07-06 | — | — | US | claimed |
| US-6713478-B2 | SUCH AS 8-BROMO-6-(3-CHLORO-4-FLUOROPHENYL)-4,4-DIMETHYL-1,4-DIHYDRO-2H-3,1 -BENZOXAZIN-2-ONE; PROGESTERONE RECEPTOR ANTAGONISTS | WYETH | 2004-03-30 | — | — | US | claimed |
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2003-11-20 | — | — | US | claimed |
| US-6566358-B2 | 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma | WYETH | 2003-05-20 | — | — | US | claimed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | claimed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | claimed |
| JP-2002543155-A | — | — | 2002-12-17 | — | — | JP | claimed |
| JP-2002543193-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | claimed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | PGR 2/4885AR 20/4885NR3C1 46/4885 |
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C2, NR5A1, PGR | PGR 3/4885AR 21/4885NR3C1 4/4885 |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | PGR, NR3C2, NR5A1 | PGR 1/4885AR 22/4885NR3C1 4/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | PGR 1/4885AR 21/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.